← Human Trials & Peer-Reviewed Studies
Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II
Plain-language guide to PMID 8390508 (1993): double-blind randomized controlled trial study of ANP (Atrial Natriuretic Peptide) and Angiotensin II in 12 patients.
Key Facts
- PMID
- 8390508
- Journal
- Journal of hypertension
- Year
- 1993
- Study type
- Randomized Controlled Trial
- Authors
- Richards AM et al. (7 authors)
- DOI
- 10.1097/00004872-199304000-00011
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of ANP (Atrial Natriuretic Peptide) and Angiotensin II, published as a randomized controlled trial.
To determine the renal, endocrine and haemodynamic effects of an orally active inhibitor of the neutral endopeptidase EC 3.4.24.11 in essential hypertension.
Who Took Part
According to the abstract, 12 patients were involved.
PubMed indexes the participants as adults and middle-aged adults, men only.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the patients nor the staff measuring them knew who was on ANP (Atrial Natriuretic Peptide), so expectations could not easily colour the readings.
Some patients received a placebo instead of ANP (Atrial Natriuretic Peptide), giving a reference point.
Each person switched between ANP (Atrial Natriuretic Peptide) and the comparison at some point, usually with a gap in between.
The methods mention a period of 5 days.
What Was Measured
PubMed files the paper under topics including Angiotensin II, Atrial Natriuretic Factor, Blood Pressure, Heart Rate, Hypertension, Indans and Kidney.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) and Angiotensin II in 12 patients over 5 days.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1993 (Journal of hypertension), a journal based in Netherlands.
More context: the ANP (Atrial Natriuretic Peptide) compound page and the Angiotensin II compound page, all human trials.
Our Notes on the Compounds
ANP (Atrial Natriuretic Peptide): A 28-amino-acid heart hormone that relaxes blood vessels and increases salt excretion; carperitide is a recombinant form.
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.